bFGF and FGF Receptor-1 Int Arch Allergy Immunol 2011;155:12-22 13 lium in asthmatics compared to nonasthmatic controls [6] , increased bFGF in sputum of mild asthmatics (forced expiratory volume in 1 s 89% predicted) compared to controls [7] and increased bFGF release into bronchoalveolar lavage (BAL) fluid 10 min after segmental allergen challenge [8] .
bFGF is a member of the FGF gene family, which comprises 23 members [9] [10] [11] [12] [13] that share approximately 30-70% identity in their primary sequence [11] . Cellular sources of bFGF include macrophages [14] , endothelial cells [14] , mast cells [15] , epithelial cells [14] and fibroblasts [14] . Like FGF-1 (also known as acidic FGF), bFGF does not contain a signal sequence for secretion [10, 11, 13] . Although bFGF does not express a secretory signal peptide, it has been detected extracellulary in vitro [16, 17] and in vivo in subjects with asthma [6, 8] . FGFs signal by binding to 1 of 4 high-affinity FGF receptors that have been identified (i.e. FGF receptor-1 to -4) [10, 11, 13] . Most FGFs bind to all 4 FGF receptors [10, 11, 13] . FGF receptors appear to be similar to other growth factor receptors in that dimerization of receptor monomers upon ligand binding activates the tyrosine kinase domain of the FGF receptor [12] . FGF receptor activation leads to tyrosine autophosphorylation of the receptor [10, 11, 13] . The glycosaminoglycans heparan sulfate and heparin have been shown to be critical for FGF receptor function [10, 11, 13] .
Although human studies have investigated the expression of bFGF in asthma [6] [7] [8] , previous studies have not investigated whether bFGF and FGF receptors are expressed in allergen-induced airway remodeling. Therefore, in this study we have utilized a mouse model of allergen-induced airway remodeling to determine which cell types express bFGF and FGF receptor-1 in the remodeled airway, as well as to determine whether the expression of bFGF in the remodeled airway may upregulate expression of additional cytokines such as transforming growth factor (TGF)-␤ 1, which may play an important role in airway remodeling in asthma [18, 19] . Finally, we investigate whether corticosteroids influence levels of bFGF and FGF receptor-1 in the remodeled airway.
Materials and Methods

Mouse Model of Chronic Ovalbumin-Induced Airway Remodeling
Eight-to 10-week-old BALB/c mice (16 mice/group; The Jackson Laboratory, Bar Harbor, Me., USA) were immunized subcutaneously on days 0, 7, 14 and 21 with 25 g of ovalbumin (OVA; OVA grade V, Sigma) adsorbed to 1 mg of alum (Aldrich) in 200 l of normal saline as previously described [18, 20] . Intranasal OVA challenges (20 g/50 l in PBS) were administered on days 27, 29 and 31 under isoflurane (Vedco Inc., St. Joseph, Mo., USA) anesthesia. Intranasal OVA challenges were then repeated twice a week for 3 months. Age-and sex-matched control mice were sensitized but not challenged with OVA during the 3-month study period. Mice were sacrificed 24 h after the final OVA challenge, and BAL fluid and the lungs were analyzed. Lungs from the different groups of mice were equivalently inflated with an intratracheal injection of a similar volume of 4% paraformaldehyde solution (Sigma Chemicals, St. Louis, Mo., USA) to preserve the pulmonary architecture and were processed as a batch for either histologic staining or immunostaining under identical conditions. Three to 5 fields were quantified on all stained and immunostained slides of lung tissue under identical light microscope conditions, including magnification ( ! 20), gain, camera position and background illumination, as previously described [18] . The quantitative histologic and image analysis of all coded slides was performed by research associates blinded to the coding of the slides. All animal experimental protocols were approved by the Animal Subjects Committee of the University of California San Diego.
Quantitation of bFGF Levels in BAL
The concentration of bFGF in BAL fluid was assayed by ELISA (R&D Systems, Minneapolis, Minn., USA). The bFGF ELISA has a sensitivity of 3 pg/ml.
Quantitation of bFGF in the Lung
Lung sections were processed for immunohistochemistry using an anti-bFGF antibody (Ab; Santa Cruz Biotechnology, Santa Cruz, Calif., USA) as previously described [18, 20] . Species-and isotype-matched Abs were used as controls. The number of bFGF+ cells was quantitated both in the lung (excluding the bronchial epithelium) and separately in the bronchial epithelium. The number of bFGF+ cells was quantitated in a ! 20 lung field by counting all the bFGF+ cells in the lung field (area of approximately 0.04 mm 2 ). Results are expressed as the number of bFGF+ cells per square millimeter of lung field. In addition, the area of bronchial epithelial cells/bronchus staining positive for bFGF was quantitated.
Quantitation of FGF Receptor-1 Expression in the Lung
Lung sections were processed for immunohistochemistry using an anti-FGF receptor-1 Ab (Calbiochem, San Diego, Calif., USA) as previously described [18, 20] . Species-and isotypematched Abs were used as controls. The number of FGF receptor-1+ cells was quantitated both in the peribronchial region (excluding the bronchial epithelium) and separately in the bronchial epithelium. Results are expressed as the number of peribronchial cells staining positive for FGF receptor-1 per bronchiole with an internal diameter of 150-200 m, as well as the area of bronchial epithelial cells/bronchus staining positive for FGF receptor-1.
Double-Label Immunofluorescence Staining with Anti-F4/80
Ab and either Anti-bFGF or Anti-FGF Receptor-1 Ab Lung sections were also immunostained with both an F4/80 primary Ab (rat anti-mouse F4/80 antigen; Accurate Chemical & Scientific Corporation, Westbury, N.Y., USA) and either a bFGF or FGF receptor-1 Ab to determine whether F4/80+ peribronchi-al cells expressed either bFGF or FGF receptor-1. The two different primary antibodies were detected using two different horseradish peroxidase (HRP) enzyme-labeled secondary antibodies with tyramide signal amplification (Molecular Probes) according to the manufacturer's instructions as previously described [18] . The anti-bFGF or anti-FGF receptor-1 Ab was detected with an HRP-labeled secondary Ab (Alexa 546, red), while the anti-F4/80 Ab was detected with a different HRP-labeled secondary Ab (Alexa 488, green). Cells coexpressing F4/80 and either bFGF or bFGF receptor-1 stain a blended yellow color.
TGF-␤ 1 Expression in Lung in vivo
The concentrations of TGF-␤ 1 in lung were assayed by ELISA as previously described [18] . Prior to the TGF-␤ 1 assay, the BAL fluid samples were treated with 2.5 N acetic acid to activate any latent TGF-␤ 1, as previously described [18, 20] .
Double-Label Immunofluorescence Staining to Detect
Coexpression of bFGF and TGF-␤ 1 Lung sections were also immunostained with both anti-bFGF and anti-TGF-␤ 1 Abs [20] to determine whether peribronchial cells co-expressed bFGF and TGF-␤ 1. The anti-bFGF Ab was detected with an HRP-labeled secondary Ab (Alexa 546, red), while the anti-TGF-␤ 1 Ab was detected with a different HRP-labeled secondary Ab (Alexa 488, green). Cells coexpressing bFGF and TGF-␤ 1 stain a blended yellow color.
Immunohistochemistry to Detect Expression of bFGF and TGF-␤ 1 by Peripheral Blood Mononuclear Cells
Peripheral blood was collected into EDTA-containing tubes from mice by means of cardiac puncture. Erythrocytes were lysed using a 1: 10 solution of 100 m M potassium carbonate and 1.5 M ammonium chloride. The remaining cells were resuspended in 1 ml of PBS. To perform immunohistochemistry, 200 l of resuspended peripheral blood leukocytes were cytospun onto microscope slides and air-dried. Slides were immunostained with either an anti-bFGF Ab or an anti-TGF-␤ 1 Ab as described above. The percentage of mononuclear cells that stained positive for either bFGF or TGF-␤ 1 was recorded for each slide.
Effects of bFGF on TGF-␤ 1 Expression by Bone Marrow-Derived Macrophages in vitro
In these experiments, 5 ! 10 5 macrophages derived from culture of mouse bone marrow using methods previously described [21] were incubated with media alone or stimulated with bFGF (10 and 100 ng/ml) in triplicate for 72 h. Supernatants were collected and assayed for TGF-␤ 1 by ELISA (R&D Systems) as previously described [20] .
Therapeutic Intervention with Corticosteroids
To determine whether corticosteroids could modulate levels of bFGF and FGF receptor-1 expression, different groups of mice (16 mice/group) were administered either dexamethasone (1 mg/kg in 100 l of sterile, endotoxin-free PBS) or diluent control intraperitoneally as previously described [22] . The first dose of corticosteroid or diluent was administered 6 h before the first intranasal OVA challenge, and the therapeutic intervention was continued daily for the duration of the 3-month period of twice weekly OVA challenges. We have previously demonstrated that this dose of corticosteroid inhibits airway remodeling in this mouse model [22] . We also examined whether corticosteroids could reduce the number of bFGF+ cells per bronchus when administration of dexamethasone was only started at the end of the 3-month OVA sensitization and challenge protocol. In these 4-month experiments (3 months of OVA + no dexamethone, 1 month of OVA + dexamethasone), we used lung specimens stored at -80 ° C from mice (16 mice/group) administered either dexamethasone (1 mg/ kg in 100 l of sterile, endotoxin-free PBS) or diluent daily for 1 month in experiments previously reported for outcomes other than bFGF [22] .
Airway Eosinophilic Airway Inflammation and Airway
Remodeling BAL eosinophils: BAL total eosinophil counts were assessed as previously described [18, 20] .
Peribronchial fibrosis: The area of peribronchial trichrome staining in paraffin-embedded lung was outlined and quantified using a light microscope (Leica DMLS; Leica Microsystems Inc., New York, N.Y., USA) attached to an image analysis system (Image-Pro Plus; Media Cybernetics, Bethesda, Md., USA) as previously described [18, 20] . Results are expressed as the area of trichrome staining per micrometer of basement membrane of bronchioles with an internal diameter of 150-200 m.
Statistical Analysis
Results in the different groups of mice were compared by ANO-VA using the nonparametric Kruskal-Wallis test followed by posttesting using Dunn's multiple comparison of means. All results are presented as means 8 SEM. A statistical software package (Graph Pad Prism, San Diego, Calif., USA) was used for the analysis. p values of ! 0.05 were considered statistically significant.
Results
Chronic OVA Challenge Induces Eosinophilic Airway Inflammation and Airway Remodeling
Repetitive OVA challenge in wildtype mice induced a significant increase in the number of BAL eosinophils (p = 0.0001, no OVA vs. OVA; fig. 1 a) as well as features of airway remodeling, including peribronchial fibrosis as assessed by trichrome staining ( fig. 2 ) as previously described [18, 20] .
Administration of corticosteroids significantly reduced levels of BAL eosinophils in chronic OVA-challenged mice by approximately 85% (p = 0.0001, no OVA vs. OVA; fig. 1 a) . Similarly, administration of corticosteroids significantly reduced levels of peribronchial fibrosis in chronic OVA-challenged mice as previously described ( fig. 2 a-d) [21, 22] .
Chronic OVA Challenge Induces Increased bFGF Levels in BAL Fluid
Chronic OVA challenge induced a significant increase in levels of BAL bFGF (OVA vs. no OVA: 158.7 8 12.2 vs.
74.3 8 7.8 pg/ml; p = 0.0001; fig. 1 b) . Corticosteroids significantly reduced levels of BAL bFGF in mice subjected to repetitive OVA challenge (corticosteroids + OVA vs. OVA: 114.2 8 13.5 vs. 158.7 8 12.2 pg/ml; p = 0.005; fig. 1 b) .
Chronic OVA Challenge Induces Expression of bFGF by Both F4/80+ Peribronchial Mononuclear Cells and Airway Epithelial Cells
To determine which cells express bFGF in response to allergen challenge, we immunostained lung sections with an anti-bFGF Ab. These studies demonstrated no bFGF staining of non-OVA challenged lungs ( fig. 3 a) , but significant bFGF immunostaining of both peribronchial mononuclear cells and airway epithelial cells in OVA-challenged mice ( fig. 3 b) . Administration of corticosteroids to OVA-challenged mice significantly reduced levels of bFGF immunostaining of both peribronchial mononuclear cells and airway epithelial cells ( fig. 3 c) .
To determine the identity of the peribronchial mononuclear cells that were bFGF+, we immunostained lung sections with both anti-bFGF ( fig. 3 d) and anti-F4/80 ( fig. 3 e) Abs. These studies demonstrated that the vast majority of bFGF+ cells were F4/80+ ( fig. 3 f) .
Quantitation of bFGF+ Peribronchial Mononuclear Cells and bFGF+ Airway Epithelial Cells
Utilizing image analysis, we quantitated the number of bFGF+ cells in the different groups of mice. Repetitive OVA challenge induced a significant increase in the num- 
Chronic OVA Challenge Induces Expression of FGF Receptor-1 Expression by F4/80+ Peribronchial Cells
To determine whether FGF receptor-1 (in addition to bFGF) was expressed in response to allergen challenge, we immunostained lung sections with an anti-FGF receptor-1 Ab. These studies demonstrated minimal FGF receptor-1 immunostaining of non-OVA challenged lungs ( fig. 6 a) but significant FGF receptor-1 immunostaining of peribronchial mononuclear cells without significant staining of airway epithelium in OVA-challenged mice ( fig. 6 b) . This distribution of FGF receptor-1 expression (peribronchial mononuclear cells but not airway epithelium) differed from that of bFGF, which was expressed by both peribronchial inflammatory cells and airway epithelium. Administration of corticosteroids to OVA-challenged mice significantly reduced levels of FGF receptor-1 immunostaining of peribronchial mononuclear cells ( fig. 6 c) .
Chronic OVA Challenge Induces Expression of FGF Receptor-1 by F4/80+ Peribronchial Mononuclear Cells
To determine the identity of the peribronchial mononuclear cells that were FGF receptor-1+, we immunostained lung sections with both anti-FGF receptor-1 ( fig. 6 d) and anti-F4/80 ( fig. 6 e) Abs. These studies demonstrated that the vast majority of FGF receptor-1+ cells were F4/80+ ( fig. 6 f) .
Quantitation of FGF Receptor-1+ Peribronchial Mononuclear Cells
Utilizing image analysis, we quantitated the number of fig. 7 a) .
Chronic OVA Challenge Induces Expression of Both bFGF and TGF-␤ 1 by Macrophages in the Remodeled Airway
Repetitive OVA challenge induced a significant increase in levels of bFGF ( fig. 1 b) as well as an associated significant increase in lung TGF-␤ 1 (OVA vs. no OVA: fig. 7 b) . Corticosteroids significantly reduced levels of lung bFGF ( fig. 1 b) and also lung TGF-␤ 1 (OVA vs. OVA + corticosteroid, p = 0.04; fig. 7 b) .
bFGF and TGF-␤ 1 Are Coexpressed by Peribronchial Mononuclear Cells in the Remodeled Airway
We utilized double-label immunofluorescence microscopy to determine whether peribronchial macrophages coexpress bFGF and TGF-␤ 1. Figure 7 c-e demonstrates that the vast majority of bFGF+ peribronchial mononuclear cells in the remodeled airway are also TGF-␤ 1+.
Assessment of Peripheral Blood Mononuclear Cell Expression of bFGF and TGF-␤ 1
Immunohistochemistry studies demonstrated that peripheral blood mononuclear cells did not express either bFGF ( fig. 7 f) or TGF-␤ 1 ( fig. 7 g ) following OVA challenge. This contrasted with the large number of lung macrophages that expressed both bFGF ( fig. 4 a) and TGF-␤ 1 ( fig. 7 d) following OVA challenge.
bFGF Induces Bone Marrow-Derived Macrophages to Express TGF-␤ 1 in vitro
As our immunohistochemistry studies demonstrated that bFGF receptors in the remodeled airway were predominantly expressed by F4/80+ mononuclear cells, we examined in vitro whether activation of bFGF receptors on bone marrow-derived macrophages would induce expression of pro-airway remodeling cytokines such as TGF-␤ 1. In these studies, incubation of purified populations of bone marrow-derived macrophages with varying concentrations of bFGF demonstrated that 100 ng/ml bFGF induced macrophages to release significant amounts of TGF-␤ 1 (bFGF vs. no bFGF: 73.2 8 7.6 vs. 15.6 8 7.4 pg/ml; p = 0.0001; fig. 8 ). 
Discussion
Overall, this study demonstrates that allergen challenge upregulates coexpression of bFGF and TGF-␤ 1 by peribronchial macrophages and that bFGF may potentiate macrophage release of TGF-␤ 1 through autocrine and/or paracrine pathways. In addition, we have demonstrated that allergen challenge induces expression of bFGF and FGF receptor-1 in the remodeled airway and that corticosteroids reduce levels of both bFGF and FGF receptor-1 in the remodeled airway. We also made the novel observation that bFGF may influence levels of air- way remodeling not only through direct mitogenic effects on structural cells such as smooth muscle [2, 3] and fibroblasts [4] , but also through indirect effects on cells such as macrophages, which are induced by bFGF to express the proremodeling cytokine TGF-␤ 1. Evidence to support the observation that bFGF induces macrophages to express TGF-␤ 1 includes in vitro studies with bone marrow-derived macrophages that express TGF-␤ 1 in response to incubation with bFGF. In addition, in vivo studies demonstrate that peribronchial F4/80+ macrophages express FGF receptor-1 and are thus able to respond to bFGF, which we demonstrated to be expressed in the remodeled airway by macrophages and airway epithelial cells. Thus, peribronchial macrophage FGF receptors may be activated by paracrine release of bFGF from airway epithelial cells, macrophages and other cells expressing bFGF in the remodeled airway, as well as potentially through autocrine release of bFGF by macrophages binding to FGF receptor-1 on the same cell. The ability of FGF receptor-1+ macrophages to respond to bFGF and release TGF-␤ 1 in vivo in the remodeled airway is suggested from double immunofluorescence studies demonstrating that individual peribronchial mononuclear cells coexpress bFGF and TGF-␤ 1. Thus, bFGF may exert proremodeling effects in the airway through direct effects on structural cells and/or indirectly through stimulation of TGF-␤ 1 expression by macrophages. Our studies demonstrating a lack of bFGF and TGF-␤ 1 expression in peripheral blood mononuclear cells suggest that the signal for induction of bFGF and TGF-␤ 1 expression likely arises in the lungs of OVA-challenged mice. Corticosteroids reduced levels of bFGF, FGF receptor-1 and TGF-␤ 1 in the remodeled airway. However, this study was unable to determine the relative contribution of bFGF-mediated TGF-␤ 1 expression to features of airway remodeling in vivo. Until studies are performed to inhibit bFGF in vivo, it is not possible to define the extent to which bFGF contributes to airway remodeling. As murine models of allergen-induced airway remodeling may or may not reflect events in human disease, further validation of these results in studies of human asthmatic subjects with airway remodeling is needed. Thus far, the majority of human studies of bFGF in asthma have studied sputum [7] and BAL [6, 8] but have not used bronchial biopsies to determine whether bFGF is associated with features of airway remodeling such as smooth muscle changes and peribronchial fibrosis. One study of atopic asthmatics demonstrated that there is a significant correlation between bFGF+ cells and bronchial submucosal vascularity [23] . As bFGF is a known inducer of angiogenesis, bFGF may play a role in mediating angiogenesis in asthma, in addition to vascular endothelial growth factor and other angiogenic cytokines. To date, no human studies have explored which cells in the airway of asthmatics express FGF receptor-1 nor examined whether bFGF expression is found in areas of airway remodeling exhibiting smooth muscle changes and peribronchial fibrosis.
While our hypothesis that bFGF expression in the remodeled airway may contribute to increased levels of TGF-␤ 1 and increased levels of airway remodeling is supported by several studies suggesting an important role for TGF-␤ 1 and Smad 2/3 in mediating airway remodeling [18, 19, 24] , there are also studies which demonstrate that an anti-TGF-␤ 1 Ab does not reduce remodeling in mice [25] . The differences in the results of these studies may be due to differences in the mouse models used in terms of the antigen dose, route of antigen delivery (intranasal vs. nebulized), duration of antigen administration (weeks vs. months) and type of antigen used (OVA vs. house dust mite extract) in the different studies [18, 19, 24, 25] . In addition, there are studies that used an acute OVA asthma mouse model not associated with airway remodeling, demonstrating that exogenous administration of bFGF reduces airway responsiveness (assessed by enhanced pause), lung inflammation and mucus [26] . Thus, further studies in which bFGF is neutralized in models of chronic allergen challenge associated with remodeling are needed to determine the role of bFGF in airway remodeling.
Studies in cell types other than lung macrophages have also examined the interaction between bFGF and TGF-␤ 1 in vitro. For example, in rat C6 glioma cells and astro- cytes, bFGF induced expression of TGF-␤ 1, which was mediated by MEK/ERK signaling and AP-1 activation [27] . In smooth muscle cells, bFGF antagonizes TGF-␤ 1-induced smooth muscle gene expression [28] . These in vitro studies suggest additional mechanisms by which bFGF and TGF-␤ 1 may interact, depending upon the responding cell type. While our in vitro studies demonstrate that bFGF can induce macrophages to express TGF-␤ 1 in vitro, the concentration of bFGF needed in vitro is higher than the levels of bFGF we detected in BAL fluid. However, the concentrations of bFGF detected in BAL may underestimate local lung macrophage concentrations of bFGF. This could be due to bFGF in BAL being diluted with the lavage fluid as well as the fact that BAL levels reflect a different compartment from the airway and may not accurately reflect higher levels of bFGF at the cell surface of macrophages in tissues. Interestingly, in vivo studies have demonstrated persistent subcutaneous fibrosis in newborn mice injected with both bFGF and TGF-␤ 1 [29] , underscoring the potential importance of coexpression of bFGF and TGF-␤ 1 to airway remodeling. In this study, we focused on the contribution of macrophage expression of bFGF and TGF-␤ 1 to airway remodeling. However, the macrophage is not the only cellular source of TGF-␤ 1 in mouse models of allergen-induced airway remodeling, as peribronchial eosinophils are also a significant source of TGF-␤ 1 [20] . Human studies of asthmatics have also demonstrated that both macrophages [30] and eosinophils [31, 32] are important sources of TGF-␤ 1. In addition, structural cells such as epithelial cells can contribute to levels of TGF-␤ 1 in asthma [24] . Thus, while our study demonstrates that macrophages express TGF-␤ 1 in the remodeled airway, other cellular sources of TGF-␤ 1 can also contribute to airway remodeling.
In summary, in this study we have demonstrated that bFGF and FGF receptor-1 expression is upregulated in the remodeled airways of mice chronically challenged with allergen. bFGF expression is induced in peribronchial macrophages that express FGF receptor-1, suggesting that macrophages could be activated through autocrine release of bFGF and/or paracrine release of bFGF from airway epithelial cells or macrophages. In vitro studies demonstrated that bFGF induces macrophages to express the proremodeling cytokine TGF-␤ 1, while in vivo studies demonstrated that macrophages coexpress bFGF and TGF-␤ 1, supporting the notion that autocrine and/or paracrine production of bFGF may induce macrophage TGF-␤ 1 expression. Finally, we demonstrated that corticosteroids reduce levels of bFGF, FGF receptor-1 and TGF-␤ 1 in the remodeled airway. Further studies in which bFGF or FGF receptor-1 are neutralized in vivo in mice and humans are needed to determine their role in allergen-induced airway remodeling.
